Evidence map›Paper›PMID 34553331›Full record

ArticleBrain imaging and behavior2022

Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment.

Ignacio Aracil-Bolaños, Frederic Sampedro, Juan Marín-Lahoz, Andrea Horta-Barba, Saül Martínez-Horta, José María Gónzalez-de-Echávarri, Jesús Pérez-Pérez, Helena Bejr-Kasem, Berta Pascual-Sedano, Mariángeles Botí and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Brain imaging and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Ignacio Aracil-BolañosMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Frederic Sampedro *Institut d'Investigacions Biomèdiques- Sant Pau (IIB-Sant Pau), Barcelona, Spain.
Juan Marín-Lahoz *Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Andrea Horta-BarbaMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Saül Martínez-HortaMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
José María Gónzalez-de-EchávarriNeurology Department, Sant Pau Hospital, Barcelona, Spain.
Jesús Pérez-PérezMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Helena Bejr-KasemMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Berta Pascual-SedanoMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Mariángeles BotíMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Antonia CampolongoMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Cristina IzquierdoMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Alexandre GironellMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain.
Beatriz Gómez-AnsónDepartament de Medicina, Universitat Autònoma de Barcelona (U.A.B.), Barcelona, Spain.
Jaime KulisevskyMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain. jkulisevsky@santpau.cat.
Javier PagonabarragaMovement Disorders Unit, Neurology Department, Sant Pau Hospital, Mas Casanovas 90-08041, Barcelona, Spain. jpagonabarraga@santpau.cat.
Hospital de Sant Pau · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESUniversitat Autònoma de Barcelona · ES

Funding

Fundació la Marató de TV3 20142910Instituto de Salud Carlos III FIS Grant PI14/02058
6 · The paper itself

Abstract

Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with consistent structural and functional brain changes. Whether different approaches for diagnosing PD-MCI are equivalent in their neural correlates is presently unknown. We aimed to profile the neuroimaging changes associated with the two endorsed methods of diagnosing PD-MCI. We recruited 53 consecutive non-demented PD patients and classified them as PD-MCI according to comprehensive neuropsychological examination as operationalized by the Movement Disorders Task Force. Voxel-based morphometry, cortical thickness, functional connectivity and graph theoretical measures were obtained on a 3-Tesla MRI scanner. 18 patients (32%) were classified as PD-MCI with Level-II criteria, 19 (33%) with the Parkinson's disease Cognitive Rating Scale (PD-CRS) and 32 (60%) with the Montreal Cognitive Assessment (MoCA) scale. Though regions of atrophy differed across classifications, reduced gray matter in the precuneus was found using both Level-II and PD-CRS classifications in PD-MCI patients. Patients diagnosed with the PD-CRS also showed extensive changes in cortical thickness, concurring with the MoCA in regions of the cingulate cortex, and again with Level-II regarding cortical thinning in the precuneus. Functional connectivity analysis found higher coherence within salience network regions of interest, and decreased anticorrelations between salience/central executive and default-mode networks in the PD-CRS classification for PD-MCI patients. Graph theoretical metrics showed a widespread decrease in node degree for the three classifications in PD-MCI, whereas betweenness centrality was increased in select nodes of the default mode network (DMN). Clinical and neuroimaging commonalities between the endorsed methods of cognitive assessment suggest a corresponding set of neural correlates in PD-MCI: loss of structural integrity in DMN structures, mainly the precuneus, and a loss of weighted connections in the salience network that might be counterbalanced by increased centrality in the DMN. Furthermore, the similarity of the results between exhaustive Level-II and screening Level-I tools might have practical implications in the search for neuroimaging biomarkers of cognitive impairment in Parkinson's disease.

Indexed as

Cognitive DysfunctionParkinson DiseaseBrainHumansMagnetic Resonance ImagingNeuropsychological TestsDefault mode networkFunctional neuroimagingParkinson’s diseaseSalience network

Identifiers

PMID34553331
OpenAlexW3201385250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.